Skip to main content
Gastro Hep Advances logoLink to Gastro Hep Advances
. 2026 Mar 24;5(6):100936. doi: 10.1016/j.gastha.2026.100936

Predicting Cancer in Inflammatory Bowel Disease Starts With Good Notes

Kit Curtius 1,2,3,∗
PMCID: PMC13098569  PMID: 42022528

Models for colorectal cancer (CRC) risk prediction in patients with inflammatory bowel disease are freely available in validated online calculators to use during shared decision-making.1, 2, 3 The statistical models use standard variables typically included in colonoscopy and pathology reports that can then be captured as free text in the electronic health record and interpreted by increasingly accurate large language models.4 By incorporating artificial intelligence, we will soon have tools that automatically extract variables, combine different risk weighting for each variable, and project predicted CRC risk in the electronic health record without additional human effort. This will give precious time back to patients and health-care providers at the bedside. However, the accuracy of these models critically hinges on appropriate documentation in the procedure and pathology notes. When variables such as biopsy location and nature (eg, random vs targeted), lesion characteristics or lack thereof, severity of inflammation, among others, are uncertain from the notes, artificial intelligence methods cannot reliably assign a risk category or predict the patient’s future CRC risk. Taking thorough notes, and ultimately using standardized note templates, is worthwhile both for creating data fit for research purposes (such as training/testing new models) and for real-time model implementation with patients, which is imminent for medicine.

graphic file with name fx1.jpg

Footnotes

Conflicts of Interest: The author discloses no conflicts.

Funding: This work was supported in part by a Merit Review Award I01 BX005958 from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service. The contents do not represent the views of the US Department of Veterans Affairs or the United States Government. This work was also supported by AGA Research Foundation (AGA Research Scholar Award AGA2022–13–05), NIH grants (R01 CA270235, P30 CA023100), and in part by the NIDDK-funded San Diego Digestive Diseases Research Center (P30 DK120515).

Ethical Statement: The study did not require the approval of an institutional review board.

References

  • 1.Curtius K., Kabir M., Al Bakir I., et al. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut. 2022;71:705–715. doi: 10.1136/gutjnl-2020-323546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wijnands A.M., Penning de Vries B.B.L., Lutgens M.W.M.D., et al. Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2024;22(8):1697–1708. doi: 10.1016/j.cgh.2024.02.014. [DOI] [PubMed] [Google Scholar]
  • 3.East J.E., Gordon M., Nigam G.B., et al. British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. Gut. 2026;75:442–475. doi: 10.1136/gutjnl-2025-335023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Johnson B., Eddington H., Kabir M., et al. Automated phenotyping with artificial intelligence predicts future advanced neoplasia risk in colitis-associated low-grade dysplasia. Clin Gastroenterol Hepatol. 2026 doi: 10.1016/j.cgh.2026.01.037. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gastro Hep Advances are provided here courtesy of Elsevier

RESOURCES